Evidence map›Paper›PMID 35185658›Full record

ArticleFrontiers in psychiatry2022

Exposure to GABA

Hiroko Kotajima-Murakami, Hideo Hagihara, Atsushi Sato, Yoko Hagino, Miho Tanaka, Yoshihisa Katoh, Yasumasa Nishito, Yukio Takamatsu, Shigeo Uchino, Tsuyoshi Miyakawa and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in psychiatry, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.1field-weighted citation impact, top 27% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 9 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 1 country.

Hiroko Kotajima-MurakamiAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Hideo HagiharaDivision of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake-Shi, Japan.
Atsushi SatoAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Yoko HaginoAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Miho TanakaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Yoshihisa KatohDepartment of Obstetrics and Gynecology, Graduate School of Medicine, The University of Tokyo, Bunkyo-Ku, Japan.
Yasumasa NishitoCenter for Basic Technology Research, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Yukio TakamatsuCenter for Basic Technology Research, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Shigeo UchinoAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Tsuyoshi MiyakawaDivision of Systems Medical Science, Institute for Comprehensive Medical Science, Fujita Health University, Toyoake-Shi, Japan.
Kazutaka IkedaAddictive Substance Project, Tokyo Metropolitan Institute of Medical Science, Setagaya-Ku, Japan.
Tokyo Metropolitan Institute of Medical Science · JPFujita Health University · JPThe University of Tokyo · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Autism spectrum disorder (ASD) is a neurodevelopmental disorder that is characterized by impairments in social interaction and restricted/repetitive behaviors. The neurotransmitter γ

Indexed as

autism spectrum disorderGABAA receptorgene expressionmicroarrayodorant bindingpicrotoxinsocial interactionWGCNA

Identifiers

PMID35185658
PMCPMC8850354
OpenAlexW4210488007

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.